Prognostic Significance of Serum-soluble CD95 in Renal Cell Cancer
Author Information
Author(s): Kimura M, Tomita Y, Imai T, Saito T, Katagiri A, Tanikawa T, Takeda M, Takahashi K
Primary Institution: Department of Urology, Niigata University School of Medicine
Hypothesis
Higher levels of serum-soluble CD95 are associated with worse prognosis in renal cell cancer patients.
Conclusion
Patients with elevated serum-soluble CD95 levels have a significantly lower disease-specific survival rate.
Supporting Evidence
- Serum-soluble CD95 levels for 72 renal cell cancer patients were significantly higher than those of 17 healthy donors.
- Twenty-one of 72 patients had elevated sCD95 levels.
- The disease-specific survival rate was significantly lower in the elevated sCD95 group.
- Serum sCD95 level was shown to be an independent prognostic factor.
Takeaway
This study found that a substance in the blood called CD95 can help doctors understand how well a patient with kidney cancer might do.
Methodology
The study compared serum-soluble CD95 levels in renal cell cancer patients to healthy donors and analyzed survival rates.
Participant Demographics
72 renal cell cancer patients and 17 healthy donors.
Statistical Information
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website